Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

LSII to Launch Clinical Trials of Muse Cells to Treat Respiratory Failure in COVID-19 Patients

Filed Under: Coronavirus, Pharma Tagged With: , , , , , , ,

Mitsubishi Chemical Holdings Corp. (TYO:4188) subsidiary Life Science Institute Inc. (LSII) plans to begin clinical trials of a Muse cell-based…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Asahi Kasei Works on New iPS Treatments for Orthopedic Sector
Asahi Kasei Works on New iPS Treatments for…
Chemical and Material Manufacturers Eye Sustainable Growth in Health Care Sector
Chemical and Material Manufacturers Eye Sustainable…
Kyoto University Venture Thyas Uses iPS Cells to Generate Killer T Cells for Cancer Treatment
Kyoto University Venture Thyas Uses iPS Cells to…
Keio University Venture Looks to Achieve Breakthrough in Cardiovascular Regenerative Medicine
Keio University Venture Looks to Achieve…
Coronavirus Report – Part 27: Pandemic Sees Clinical Trials for New Drugs Suspended, Postponed
Coronavirus Report – Part 27: Pandemic Sees Clinical…
University of Tsukuba Discovers New Method to Regenerate Heart Muscle With Gene Injection
University of Tsukuba Discovers New Method to…